Nicole Casadevall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicole Casadevall has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
André Kher
1 shared publicationAnne Ebel
1 shared publicationAnnie Borel-Derlon
1 shared publicationAntoine Achkar
1 shared publicationAurélien Delluc
1 shared publication- Bertrand Condat
Services d'hépato-gastro-entérologie, de radiologie et de chirurgie viscérale, Hôpital Saint-Camille, Bry-sur-Marne, France
1 shared publication
Latest Publications
- 1 February 2014
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 12 (2) , 341-345
Risk of Pure Red Cell Aplasia in Patients With Hepatitis C Receiving Antiviral Therapy and an Erythropoiesis-Stimulating Agent
- 1 February 2014
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 12 (2) , 341-345
Risk of Pure Red Cell Aplasia in Patients With Hepatitis C Receiving Antiviral Therapy and an Erythropoiesis-Stimulating Agent
- 1 September 2011
- Published by Elsevier in Kidney International
- Vol. 80 (5) , 553
Biosimilars need comparative clinical data
- 1 September 2011
- Published by Elsevier in Kidney International
- Vol. 80 (5) , 553
Biosimilars need comparative clinical data
- 27 February 2010
- Published by Springer Nature in International Journal of Hematology
- Vol. 91 (2) , 165-173
Molecular aspects of myeloproliferative neoplasms
During these past 5 years several studies have provided major genetic insights into the pathogenesis of the so-called classical myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The discovery of the JAK2V617F mutation first, then of the JAK2 exon 12 and MPLW515 mutations, have modified the understanding of these diseases, their diagnosis, and management. Now it is established that almost 100% of PV patients present a JAK2 mutation. Nearly 60% of ET patients and 50% of patients with PMF have the JAK2V617F mutation. The MPLW515 mutations are also present in a small proportion of ET and PMF patients. These mutations are oncogenic events that cause these disorders; however, they do not explain the heterogeneity of the entities in which they occur. Genetic defects have not been yet identified in around 40% of ET and PMF. There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations. Moreover, polymorphisms in the JAK2 gene have been recently described as associated with MPN. Additional studies of large cohorts are required to dissect the genetic events in MPNs and the mechanisms of these oncogenic cooperations.
- 27 February 2010
- Published by Springer Nature in International Journal of Hematology
- Vol. 91 (2) , 165-173
Molecular aspects of myeloproliferative neoplasms
During these past 5 years several studies have provided major genetic insights into the pathogenesis of the so-called classical myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The discovery of the JAK2V617F mutation first, then of the JAK2 exon 12 and MPLW515 mutations, have modified the understanding of these diseases, their diagnosis, and management. Now it is established that almost 100% of PV patients present a JAK2 mutation. Nearly 60% of ET patients and 50% of patients with PMF have the JAK2V617F mutation. The MPLW515 mutations are also present in a small proportion of ET and PMF patients. These mutations are oncogenic events that cause these disorders; however, they do not explain the heterogeneity of the entities in which they occur. Genetic defects have not been yet identified in around 40% of ET and PMF. There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations. Moreover, polymorphisms in the JAK2 gene have been recently described as associated with MPN. Additional studies of large cohorts are required to dissect the genetic events in MPNs and the mechanisms of these oncogenic cooperations.
- 1 January 2009
- Published by Elsevier
Liste des Collaborateurs
- 1 September 2006
- p. S283-6
[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Pure red-cell aplasia is an isolated disorder of erythropoiesis that leads to the pment of severe, isolated anemia. In chronic kidney disease patients treated with n erythropoiesis stimulating agent (ESA), development of anti-erythropoietin antibodies s one of the leading causes of pure red-cell aplasia. It requires to stop treatment with ESA, but in the vast majority of cases immunosuppressive therapy is necessary to induce the disappearance of anti-erythropoietin antibodies. Isolated case reports suggest that, at least in some patients, treatments with ESA can be resumed after recovery from antibody-mediated pure red-cell aplasia.
- 1 September 2006
- p. S283-6
[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Pure red-cell aplasia is an isolated disorder of erythropoiesis that leads to the pment of severe, isolated anemia. In chronic kidney disease patients treated with n erythropoiesis stimulating agent (ESA), development of anti-erythropoietin antibodies s one of the leading causes of pure red-cell aplasia. It requires to stop treatment with ESA, but in the vast majority of cases immunosuppressive therapy is necessary to induce the disappearance of anti-erythropoietin antibodies. Isolated case reports suggest that, at least in some patients, treatments with ESA can be resumed after recovery from antibody-mediated pure red-cell aplasia.